Pharmacy benefit managers overcharged for specialty generic medications — in many cases by hundreds and thousands of percent ...

As Lina Khan, chair of the Federal Trade Commission, ends her tenure this week the FTC posted a second report in six months ...

As the 119th Congress convenes, policymakers have a historic opportunity to lower prescription drug prices for Americans. As ...

At a public meeting held on January 15, 2025, the Federal Trade Commission (FTC) summarized the Second Interim Staff Report ...

Mintz’s Health Law and Antitrust teams actively monitor federal and state regulatory and legislative developments in the PBM ...

The industry says it keeps down the cost of prescription drugs, but critics say it's profiting at the expense of patients.

Pharmacy benefit managers are the middlemen in the prescription drug market. The Federal Trade Commission reports the revenue of four PBMs exceeds $1 trillion and they control 86% of the market.

In the report, the FTC said pharmacy benefit managers (PBMs), charge significant markups for cancer, HIV, and other critical ...

Sen. James Lankford has been trying to pass legislation in response to an industry he believes will leave small towns without ...

The Federal Trade Commission published a second interim staff report on the prescription drug middleman industry, which focuses on pharmacy benefit managers’ influence over specialty generic ...

The report shows that PBMs made over $7.3 billion in extra profits from dispensing specialty generic drugs during the study ...

When talking about the influence of pharmacy benefit managers, U.S. Sen. James Lankford exhibits a mastery of how companies like CVS Health control where patients get their medicine, what ...